Core Viewpoint - The company, Boji Pharmaceutical, emphasizes its competitive edge in traditional Chinese medicine (TCM) research and development services, focusing on providing comprehensive TCM R&D services and enhancing its capabilities in the field [1] Group 1: Business Focus - The company primarily offers TCM R&D services through its wholly-owned subsidiary, Xinglin TCM, which provides clinical, preclinical, and registration services for TCM [1] - The company’s controlling subsidiary, Henan Kangli, specializes in post-marketing re-evaluation services for TCM [1] Group 2: Research and Development Achievements - In the past two years, the company has successfully developed TCM Class 1.2 CRA (raw materials and formulations) and Class 1.1 Qingzhi ointment, both of which have received the "Drug Clinical Trial Approval Notice" [1] - Several innovative TCM self-research projects are currently in the preclinical development stage [1] Group 3: Future Strategy - The company plans to continue prioritizing TCM R&D services while supplementing its self-research efforts and aims to attract more TCM R&D talent to enhance its competitiveness in the TCM sector [1]

Investment Rating - The report maintains a "Strong Buy" rating for Yangnong Chemical [2][5] Core Views - Yangnong Chemical reported a revenue of 3.241 billion yuan in Q1 2025, a year-on-year increase of 2.04%, with a net profit of 435 million yuan, up 1.35% year-on-year. The growth was driven by an increase in pesticide sales despite a slight decline in prices [3] - The company is progressing steadily with new project capacity construction, which is expected to contribute to performance growth in the future. By the end of 2024, the cumulative investment in the Liaoning Youchuang Phase I project will reach 2.783 billion yuan, accounting for 80% of the total budget [5] - The agricultural chemical industry is currently at the bottom of the cycle, but opportunities are emerging from green development, internationalization, and increased industry concentration. The demand for agricultural products is expected to rise in the long term, supported by favorable policies and increased planting areas in major producing countries [4] Financial Performance Summary - In Q1 2025, the raw material segment saw a price decline of 8.77% year-on-year, but sales volume increased by 14.82%, leading to a revenue increase of 4.75% to 1.806 billion yuan. The formulation segment experienced a price drop of 1.63% year-on-year, with a sales volume increase of 2.77%, resulting in a revenue increase of 1.10% to 871 million yuan [3] - The comprehensive gross profit margin increased by 0.3 percentage points year-on-year to 24.64%, contributing to the growth in net profit [3] - The financial forecast for 2025-2027 estimates net profits of 1.355 billion, 1.643 billion, and 2.095 billion yuan, respectively, with corresponding EPS of 3.33, 4.04, and 5.15 yuan, and current P/E ratios of 16, 13, and 10 times [5][6]

公 司 研 究 扬农化工（600486.SH）：一季度业 绩增长，项目建设有序推进 2025 年 4 月 30 日 强烈推荐/维持 扬农化工 公司报告 扬农化工发布 2025 年 1 季报：公司 1 季度实现营业收入 32.41 亿元， YoY+2.04%，归母净利润 4.35 亿元，YoY+1.35%。 农药产品销量增长，但价格小幅下滑，带动公司整体实现增长。分板块看，① 原药：1 季度公司原药产品价格同比下滑 8.77%，销量同比增长 14.82%，带 动营收同比增长 4.75%至 18.06 亿元；②制剂：1 季度公司制剂产品价格同比 下滑 1.63%，销量同比增长 2.77%，带动产品营收同比增长 1.10%至 8.71 亿 元。从利润端看，公司综合毛利率同比小幅增长 0.3 个百分点至 24.64%，带 动净利润增长。 行业尚处周期底部，但是绿色化、国际化与集中度提升也孕育着新机遇。首先， 国家高度重视粮食安全，持续推出农业利好政策以及有利于农药行业创新、绿 色、高质量发展的法律法规。其次，虽然 2024 年全球粮食价格处于周期底部， 但粮食需求中长期需求明确，广大发展中地区居民饮食结构仍有较大改善 ...